Celera Genomics, the Maryland-based company in the forefront of the race to
unravel the human genome, said last week that it had sequenced 95 per cent of
the mouse genome, from three strains. “The mouse genome is an invaluable tool to
interpret the human genome,” says Craig Venter, Celera’s president. A spokesman
for Britain’s Wellcome Trust says that its plan to spend £39 million with
the US National Institutes of 91ɫÇéƬ sequencing the genome of a fourth mouse
strain does not put them in competition with Celera. “We are sequencing a
different strain of mouse. The two approaches are complementary,” she says.
More from New Scientist
Explore the latest news, articles and features
Physics
Record-breaking, fast-spinning magnet could help uncover new physics
News
91ɫÇéƬ
Less than 4 minutes of vigorous exercise a day could halve your dementia risk
News
91ɫÇéƬ
Parkinson’s may be driven by ‘vicious cycle’ that disrupts brain waste drainage
News
Space
Hubble Space Telescope is falling to Earth – should NASA save it?
News
Popular articles
Trending New Scientist articles